Paris

• A multicenter, single-arm, open-label study to evaluate efficacy and safety of switching from anti-C5 antibody treatment to iptacopan treatm … Recruiting
  2023-504550-35-00 5 2025-04-03 Atypical Hemolytic Uremic Syndrome (aHUS)
• Ivosidenib in participants with locally advanced or metastatic conventional chondrosarcoma untreated or previously treated with 1 or 2 syste … Recruiting
  2023-508507-20-00 5 2025-04-03 Locally advanced or metastatic conventional chondrosarcoma with an IDH
• A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) i … Recruiting
  2023-507613-10-01 7 2025-03-31 Active Systemic Lupus Erythematosus;Systemic lupus erythematosus (SLE)
• MAINTAIN-POP: EXL01 and prevention of post-operative recurrence of Crohn's disease Recruiting
  2024-511357-22-00 4 2025-03-31 Crohn's disease
• A study in newly diagnosed glioblastoma patients that aims at testing the efficacy of Optune (Tumor Treating Fields), together with temozolo … Recruiting
  2024-513550-30-00 5 2025-03-28 Newly diagnosed Glioblastoma
• CHAPTER-4 – A long term trial of deucrictibant treatment in prophylaxis against HAE attacks in adults and adolescents Recruiting
  2024-516248-24-00 5 2025-03-28 Hereditary Angioedema
• Efficacy and safety of bezafibrate 400 mg and bezafibrate 200 mg as adjunctive treatments in patients with primary biliary cholangitis and n … Recruiting
  2023-504086-23-00 5 2025-03-27 Subjects with PBC with a non-optimal response to UDCA.
• Clinical trial evaluating the efficacy of pemigatinib for the treatment of patients with solid tumours with an alteration of the gene FGFR Recruiting
  2024-512729-10-00 4 2025-03-27 Recurrent or metastatic solid cancer harboring a FGFR1,2 ,3 fusion/rea
• Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chem … Recruiting
  2023-505773-32-00 10 2025-03-25 Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer
• A Basket Study of Vosoritide in Children with Turner Syndrome, Short Stature Homeobox-Containing Gene Deficiency, and Noonan Syndrome with I … Recruiting
  2024-515861-33-00 4 2025-03-25 Turner Syndrome, Short Stature Homeobox-Containing Gene Deficiency, an
• A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo and risankizumab (active reference arm) in partici … Recruiting
  2024-516219-25-00 5 2025-03-25 psoriatic arthritis
• Ziftomenib in combination with chemotherapy for children with relapsed/refractory acute leukemia Recruiting
  2023-505262-28-00 3 2025-03-24 Acute Myeloid Leukemia
• A Phase 1a/b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of PRMT5 I … Recruiting
  2024-515307-19-00 1 2025-03-24 Advanced, or metastatic solid tumors with methylthioadenosine phosphor
• KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors Recruiting
  2024-513285-19-00 1 2025-03-14 Pancreatic Ductal Adeno Carcinoma
• Study to evaluate efficacy and safety of inclisiran in children aged 6 to under 12 years of age with heterozygous familial hypercholesterole … Recruiting
  2024-514594-21-00 5 2025-03-13 Heterozygous Familial Hypercholesterolemia
• A study to learn if bimekizumab is safe and how it moves throughout the body in children with certain types of juvenile idiopathic arthritis Recruiting
  2023-508845-41-00 5 2025-03-11 Active juvenile idiopathic arthritis subtypes enthesitis-related arthr
• A study to assess the efficacy and safety of lumateperone in patients with major depressive disorder Recruiting
  2023-503836-41-00 5 2025-03-10 Major Depressive Disorder
• Lutathera for the treatment of recurrent Meningioma (LUMEN-1) Recruiting
  2024-513443-93-00 4 2025-03-10 Recurrent Meningioma without local treatment options (Surgery or Radio
• LYSARI – LYmphocyte-Sparing And Radio-Immunotherapy in Head and neck carcinoma - A multicenter, randomised 2*2 factorial design comparing st … Recruiting
  2022-501315-13-00 5 2025-03-06 Patients with lateralised oropharyngeal, laryngeal and hypopharyngeal
• First-line immunotherapy-based standard of care and local ablative treatments for oligometastatic non-small cell lung cancer patients: a ran … Recruiting
  2023-503326-39-00 5 2025-03-06 Synchronous oligometastatic non-small cell lung cancer (NSCLC)
• Capecitabine plus pembrolizumab in patients with triple negative breast cancer after chemoimmunotherapy and surgery Recruiting
  2023-505291-30-01 4 2025-03-06 Triple Negative Breast Cancer with residual disease after neoadjuvant
• A trial to learn if AZD0486 alone or with other anticancer drugs is safe and works in adults with certain blood cancers Recruiting
  2024-515034-33-00 9 2025-03-05 Mantle Cell Lymphoma
• Chimiothérapie à base de bevacizumab adaptée à la pharmacocinétique du bevacizumab en 1ère ligne de traitement du cancer colorectal métastat … Recruiting
  2023-507873-16-00 11 2025-03-04 1st line treatment for unresectable metastatic colorectal cancer
• Portal hypertension in cirrhosis Recruiting
  2023-508535-32-00 4 2025-03-04 Portal hypertension (PHT) and consequences in complications of cirrhos

Showing 769–792 of 2,286 trials